The interleukin inhibitor market also grew rapidly in the first quarter. Compared to the first quarter of last year, the market size increased by 26% in one year.

While Stelara, the market leader, posted sales of KRW 11.1 billion, up 9.8% YoY, generics are rapidly catching up. Skyrizi saw a 69.7% year-over-year increase in sales and Tremfya's 43.4%. In particular, as generics are scrambling to add new content and expand the scope of reimbursement, competition in this market is expected to intensify in the future. The interleukin inhibitor market increased by 26% in 1 year, and Stelara remains No. 1 in the market for 12 years

According to IQVIA, a pharmaceutical market research institute